AOL

Medtronic ratchets up patent spat for device that aids in bladder, bowel control

Medtronic is upping the ante in patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic's InterStim device, an implanted ...
MD&M East

Medtronic Scores FDA Nod for Next-Gen InterStim

Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
BioWorld

Stimguard set to study its tibial nerve OAB system against Medtronic's Interstim device

Stimguard LLC will begin enrollment for a head-to-head study of its Chronic Affarent Nerve Stimulator (CAN-stim) against Medtronic plc's gold standard Interstim device in treatment of urgency urinary ...

Patients get rare tour of Medtronic to meet - and thank - employees

BROOKLYN CENTER, Minn. — Medtronic is giving a group of international VIPs a rare, behind the scenes tour of its operations ...
WWLP-22News

Medtronic receives FDA approval for InterStim X™ system, the next generation of the most personalized sacral nerve stimulation therapy for bladder and bowel control

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...
Reuters

US appeals court revives Axonics challenges to Medtronic device patents

Axonics gets a new chance to invalidate two Medtronic nerve-stimulation patents Related Medtronic lawsuit scheduled for trial in August The U.S. Court of Appeals for the Federal Circuit said, opens ...
FierceBiotech

Medtronic asks ITC to wade into Axonics patent spat, filing request for exclusion order

As Medtronic and Axonics’ legal battle over alleged similarities between their sacral neuromodulation devices drags on, Medtronic is getting the U.S. International Trade Commission involved. The ...
Business Insider

Medtronic Announces Comprehensive U.S. Launch of New InterStim™ Micro Neurostimulator

DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for sacral ...
Nasdaq

U.S. Patent Office Completes Review of Medtronic Patents, Rejects More Axonics Challenges

DUBLIN, Sept. 22, 2021 /PRNewswire/ -- Medtronic (NYSE:MDT), the global leader in medical technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark ...
Nasdaq

Medtronic announces first patient implants of investigational implantable tibial neuromodulation therapy for bladder incontinence

DUBLIN, March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the first patient implants in the TITAN 2 pivotal study that will evaluate ...
BioWorld

Medtronic files for FDA approval of Interstim Micro, Surescan MRI leads

Dublin-based Medtronic plc has filed a PMA supplement with the U.S. FDA for its next-generation, implantable sacral neuromodulation (SNM) device, Interstim Micro, and for its Interstim Surescan MRI ...